Teva Pharmaceutical Industries Limited
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Richard D. Francis
- Full Time Employees
- 32,008
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 124 Dvora Hanevi’a Street Tel Aviv TA Israel 6944020
- IPO Date
- Feb 16, 1982
- CIK
- 0000818686
- Website
- tevapharm.com
- Similar Companies
- Business
- Teva Pharmaceutical Industries Limited, an Israeli multinational pharmaceutical company founded in 1901 and headquartered in Petah Tikva, Israel, develops, manufactures, markets and distributes generic medicines, innovative branded drugs, biopharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products worldwide across more than 60 countries with manufacturing facilities in Israel, North America, Europe, Australia and South America; core generic offerings span various dosage forms including tablets, capsules, ointments, creams, liquids, injectables and inhalants for therapeutic areas such as pain management, cardiovascular diseases, infectious diseases, central nervous system disorders, respiratory conditions, oncology and generics leadership in complex products; key innovative medicines include AUSTEDO (deutetrabenazine) for chorea in Huntington's disease and tardive dyskinesia, AJOVY (fremanezumab) for migraine prevention, UZEDY for schizophrenia, Copaxone for multiple sclerosis and a pipeline featuring olanzapine LAI, duvakitug for inflammatory bowel disease, DARI asthma inhaler, emrusolmin and TEV-56278 (anti-PD1-IL2 ATTENUKINE) for oncology. The company operates in segments including generics and biosimilars targeting healthcare providers, pharmacies and hospitals globally, with a focus on neuroscience, immunology, respiratory diseases and pain management customer bases. Teva advances its Pivot to Growth strategy, launched in 2023 and accelerated in 2025, to build a greater than $5 billion innovative medicines franchise by 2030 through robust late-stage pipeline execution, 25 to 27 biosimilar launches by 2027 including eculizumab-aagh with Samsung Bioepis and PONLIMSI/DEGEVMA denosumab biosimilars approved in Europe; recent strategic partnerships encompass a June 2025 collaboration with Fosun Pharma for TEV-56278 development in Asia, a prior alliance with Sanofi for TEV-574 anti-TL1A in inflammatory bowel disease, and the November 2025 launch of Teva Rise open innovation platform for AI, digital health and manufacturing advancements; ongoing efforts include divestiture of its API business TAPI announced in 2024, eleven consecutive quarters of revenue growth as of Q3 2025 driven by 33% innovative portfolio increase in local currency, reaffirmed 2027 targets of 30% operating profit margin, over $2.7 billion free cash flow and $2.5 billion Estero revenues with peak sales exceeding $3 billion, alongside credit upgrades reflecting debt reduction and operational enhancements.
Company News
Teva to Host R&D Day on Wednesday, November 11 in New York City
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript
FDA Approves Teva's New Once-Monthly Schizophrenia Injection
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
Teva's Branded Drugs Take Center Stage in Its Growth Strategy
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
QRG Capital Management Inc. Purchases 12,925 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Teva Releases Q3 2026 Aide Memoire
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript